



NEWS

FOR IMMEDIATE RELEASE

Contact: Rebekah L. Lazarou
800-886-2966 Ext. 377
Rllazarou@cynosurelaser.com

Cynosure and DUSA Pharmaceuticals To Collaborate in Phase II Clinical Trial

Chelmsford, MA, (May 20, 2004)—Cynosure, Inc., a leading developer and manufacturer of lasers and pulsed light sources, announced that it will collaborate with DUSA Pharmaceuticals, Inc. as the exclusive provider of the V-Star™ pulse dye laser systems for DUSA's Phase II clinical study for the treatment of facial photodamage. The trial will use DUSA's Levulan® photodynamic therapy (PDT) with 3 light sources, including Cynosure's V-Star™ pulse dye laser treatment.

"Leading dermatologists consider Levulan PDT one of the most exciting developments impacting their medical and aesthetic practices", said Michael R. Davin, CEO of Cynosure. "As our population ages, the interest in non-ablative procedures to treat sun damaged skin will grow tremendously. We are pleased that we can play a role in helping DUSA explore these opportunities with our pulse dye laser technology."

Dr. Geoffrey Shulman, DUSA's President and CEO, stated "With the rapidly growing interest in Levulan PDT, dermatologists and other physicians are eager to see it developed for use in additional indications. After investigator-initiated studies using Levulan PDT with the V-Star® for treating photodamaged skin reported promising patient outcomes, DUSA's became interested in incorporating the V-Star into our new Phase II trial. We are delighted to be working with Cynosure, a pioneer in this field."

Dr. Roy Geronemus, past President of the American Society of Dermatologic Surgery (ASDS), referencing ASDS statistics, noted that "The number of non-ablative photorejuvenation (NAPR) treatments for photoaging has increased by 60% over the last 3 years. In this study, the goal is to determine whether the addition of Levulan to NAPR will provide even better results for patients."

Mark S. Nestor, M.D., Ph.D., an advisor to both companies, stated that "Levulan PDT is now being routinely used in our practice with the V-Star™ for the treatment of the entire face, with excellent cosmetic results. This includes patients with significant sun damage, rosacea and even severe cystic acne."

For more information, call Cynosure at 800-886-2966 and visit www.cynosurelaser.com or call Shari Lovell, Director, Shareholder Services at DUSA Pharmaceuticals at 416-363-5059, ex. 121 and visit www.dusapharma.com.

10 Elizabeth Drive
Chelmsford, MA 01824
T 800.886.2966 - F 978-256-6556
www.cynosurelaser.com



About DUSA Pharmaceuticals (NASDAQ NMS: DUSA)

DUSA Pharmaceuticals, Inc. is a biopharmaceutical company developing and marketing its proprietary Levulan photodynamic therapy (PDT) and photodetection (PD), primarily for the treatment of dermatological indications. PDT and PD utilize light-activated compounds such as Levulan to induce a therapeutic or detection effect. DUSA is a world leader in topically or locally applied PDT and PD. The Company maintains offices in Wilmington, MA, Valhalla, NY, and Toronto, Ontario.

DUSA's Levulan® Kerastick® for Topical Solution plus blue light illumination using the BLU-U® Blue Light Photodynamic Therapy Illuminator is FDA-approved for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The FDA also cleared the BLU-U ® alone for the treatment of moderate inflammatory acne. Levulan® PDT is being investigated for use in the treatment of photodamaged skin, acne, and other dermatological and internal disorders.

About Cynosure

Cynosure develops, manufactures, and markets laser technology products at its Chelmsford, Massachusetts headquarters for worldwide distribution. The company's extensive product line includes the PhotoGenica® family of vascular treatment/ facial treatment lasers, the Apogee™ family of hair removal lasers, the Acclaim™ and SmartEpil™ multi-application cosmetic lasers, the PhotoLight® pulsed light system, the Tri-Active® LaserDermology™ for cellulite treatment and therapeutic laser massage and the PhotoGenica® SV for surgical ENT applications.

In 2002, El. En., Italy's leading laser developer and manufacturer, acquired a majority position of Cynosure, Inc. The product mix of the two companies is highly complementary and will provide opportunities for growth through an increased mix of products and wider coverage of global markets. El. En. and Cynosure are working closely to optimize joint production processes, research and development efforts, and to exploit worldwide distribution channels.

Today, over 5000 of Cynosure and El.En. lasers and light-based systems are installed around the world and are used in treating a full range of conditions.

Cynosure has offices in the United Kingdom, France, Germany, Singapore and Japan, and has forged a strategic partnership with Suzhou Cynosure Medical Devices in Suzhou, Peoples Republic of China. Cynosure's global reach extends to more than 60 nations and has given the company worldwide recognition in physician practices.

Cynosure was founded in 1991 by Dr. Horace Furumoto, who also founded Candela Corp.

10 Elizabeth Drive
Chelmsford, MA 01824
T 800.886.2966 - F 978-256-6556
www.cynosurelaser.com